(MENAFNEditorial)
GBI Research the leading business intelligence provider has released its latest research "Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth" which provides insights into type 2 diabetes in the Asia-Pacific (APAC) markets of China India Japan and Australia. The report estimates the market size for 2013 and provides a forecast until 2020 and covers disease epidemiology treatment algorithms and treatment use patterns. It also provides in-depth analysis of the pipeline molecules clinical trial failure rates and recent deals. The report has been built using data and information sourced from proprietary databases primary and secondary research and in-house analysis carried out by GBI Research's team of industry experts.
Full Report Details at
- http://www.fastmr.com/prod/924460_type_2_diabetes_therapeutics_in_asiapacific.aspx?afid=101
In 2013 the value of the type 2 diabetes therapeutics market in APAC countries was an estimated $6.5 billion and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 7.1% between 2013 and 2020 to $10.5 billion. This strong growth is due to the anticipated approval of products in relatively novel treatment classes such as Glucagon-Like Peptide-1 (GLP-1) agonists Dipeptidyl Peptidase-4 (DPP-4) inhibitors and Sodium Glucose Transporter-2 (SGLT-2) inhibitors as well as the growth of the prevalence population in the APAC region particularly in India and China.
Scope
The report analyzes the treatment use patterns market characterization pipeline analysis and key licensing and co-development deals of the type 2 diabetes in the APAC markets of China India Japan and Australia.It includes -
* A brief introduction to type 2 diabetes including its pathophysiology etiology diagnosis and treatment algorithms
* In-depth analysis of currently marketed drugs for type 2 diabetes including analysis of their safety efficacy treatment patterns and strengths and weaknesses as well as a heat map comparing them in terms of safety and efficacy
* A comprehensive review of the pipeline for type 2 diabetes including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed by Phase distribution molecule type program type mechanism of action and molecular target
* Additional in-depth analysis of pipeline drug clinical trials by Phase trial size trial duration and program failure rate for each molecule type
* Multi-scenario market forecast data to 2020 taking into account how the market might be affected by the introduction of new drugs the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets
* Discussion of the drivers of and barriers to market growth
* In-depth analysis of all licensing and co-development deals that have occurred in the type 2 diabetes market since 2006
Reasons to Get this Report
The report will enhance your decision-making capability by allowing you to -
* Understand the type 2 diabetes pipeline and the factors that indicate that it is becoming more innovative
* Examine detailed profiles for promising pipeline products and gain an insight into how and with whom they are likely to compete in the market
* Follow the trends in type 2 diabetes clinical trial size and duration in relation to industry averages
* Assess the potential risk of future developmental programs for type 2 diabetes therapeutics depending on the mechanism of action by taking into account the recorded clinical trial failure rates
* Examine the growth patterns expected for the type 2 diabetes market over the forecast period and the countries that are expected to contribute the most to this growth allowing you to devise a more effectively tailored country strategy through an understanding of key drivers and barriers
* Accelerate and strengthen your market position by identifying key companies for strategic partnerships
Partial Table of Contents:
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Symptoms
2.2 Etiology
2.3 Pathophysiology
2.4 Diagnosis
2.5 Epidemiology
2.6 Prognosis
2.7 Co-Morbidities and Complications
2.8 Treatment and Management
2.8.1 The Role of Insulin in Type 2 Diabetes
2.8.2 Non-Insulin Diabetic Drugs
2.8.3 Other Drugs
3 Marketed Products
3.1 Metformin
3.2 DPP-4 Inhibitors
3.2.1 Januvia (sitagliptin)/Janumet (sitagliptin and metformin) Merck
3.2.2 Tradjenta (linagliptin) - Boehringer Ingelheim
3.2.3 Onglyza (saxagliptin) - Bristol-Myers Squibb and AstraZeneca
3.2.4 Nesina (alogliptin) - Takeda
3.2.5 Galvus (vildagliptin) - Novartis
3.2.6 Tenelia (teneligliptin) - Daiichi Sankyo and Mitsubishi Tanabe
3.3 GLP-1 Agonists
3.3.1 Byetta and Bydureon (exenatide) - Bristol-Myers Squibb
3.3.2 Victoza (liraglutide) - Novo Nordisk
3.3.3 Lyxumia (lixisenatide) - Sanofi
3.4 Sulfonylureas
3.4.1 Glimepiride
3.4.2 Gliclazide
3.5 Thiazolidinediones
3.5.1 Actos (pioglitazone) - Takeda Pharmaceuticals
3.6 Long-Acting Insulins
3.6.1 Lantus (insulin glargine) - Sanofi
3.6.2 Levemir (insulin detemir) - Novo Nordisk
3.7 SGLT Inhibitors
3.7.1 Forxiga (dapagliflozin) - Bristol-Myers Squibb
3.7.2 Invokana (canagliflozin) - Janssen
3.8 Comparative Efficacy and Safety
4 Type 2 Diabetes Market to 2020 - Pipeline Products
4.1 Overall Pipeline
4.2 Pipeline Analysis by Molecule Type
4.3 Pipeline Analysis by Mechanism of Action
4.4 Clinical Trials
4.4.1 Failure Rate
4.4.2 Patient Enrollment and Clinical Trial Size
4.4.3 Duration
4.5 Promising Drug Candidates in the Pipeline
4.5.1 LY-2189265 (dulaglutide) - Eli Lilly
4.5.2 Albiglutide - GlaxoSmithKline
4.5.3 Ipragliflozin - Astellas Pharma
4.5.4 Semaglutide - Novo Nordisk
5 Market Forecast to 2020
5.1 Geographical Markets
5.1.1 Asia-Pacific Market
5.1.2 China
5.1.3 India
5.1.4 Japan
5.1.5 Australia
5.2 Drivers and Barriers
5.2.1 Drivers
5.2.2 Barriers
6 Deals and Strategic Consolidations
6.1 Major Licensing Deals
6.1.1 Viking Therapeutics Enters into Licensing Agreement with Ligand Pharma
6.1.2 Zosano Pharma Enters into Licensing Agreement with Novo Nordisk
Full Table of Contents is available at:
-- http://www.fastmr.com/prod/924460_type_2_diabetes_therapeutics_in_asiapacific.aspx?dt=t&afid=101
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts we provide quick and easy access to the best competitive intelligence available. Our unbiased expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.